Abstract
The paper presents a systematic analysis of experimental and clinical studies of etifoxine. The anxiolytic effect of etifoxine is due, firstly, to the modulation of GABA receptor activity and, secondly, to that of metabolism of neurosteroids that are themselves characterized by anxiolytic and neuroprotective properties. The results of clinical trials of etifoxine are also analyzed. In addition to its anxiolytic effect that partially persists even after treatment discontinuation, etifoxine is ascertained to be characterized by analgesic, neurotrophic and neuroprotective properties.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have